Asia-Pacific Electrophysiology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product and Indication

The APAC electrophysiology market is expected to grow from US$ 2,070.72 million in 2022 to US$ 3,802.83 million by 2028; it is estimated to grow at a CAGR of 10.7% from 2022 to 2028.

The introduction of technologically advanced electrophysiology devices is one of the significant elements influencing the electrophysiology market growth in the region. The use of various advanced mapping and guidance systems supporting improved cardiac rhythm monitoring is expected to increase the uptake of these devices during the forecast period. Technological innovations such as GE Healthcare's Innova IGS 520 and Optima IGS 320 are expected to provide lucrative growth opportunities to the market players. These products are dose-efficient interventional X-ray systems, enabling physicians to perform complex interventional procedures efficiently and accurately. Also, the market players offer technologically advanced solutions and new products and approvals to the healthcare industry. For instance, in January 2019, Abbott launched its sensor-enabled TachiCath Contact Force Ablation Catheter for the treatment of atrial fibrillation, which enables accurate imaging of the heart during an ablation procedure. Also, in September 2019, Johnson & Johnson (Biosense Webster) launched CARTONET, the world's first secure, cloud-based network for electrophysiologists to review, analyze, and share atrial fibrillation case data to improve procedural efficiencies. In January 2022, Abbott Laboratories, a pharmaceutical company, was granted clearance by the FDA for using the EnSite X electrophysiology system with omnipolar EnSite technology to treat patients with atrial fibrillation.

Hence, the rising prevalence of atrial fibrillation (AF), the introduction of technologically advanced solutions, and product launches and approvals are expected to boost the APAC electrophysiology market over the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC electrophysiology market at a substantial CAGR during the forecast period.

APAC Electrophysiology Market Segmentation

The APAC electrophysiology market is segmented based on product, indication, and country.

• Based on product, the market is segmented into electrophysiology ablation catheters, electrophysiology laboratory devices, electrophysiology diagnostic catheters, access devices, and others. The electrophysiology laboratory devices segment dominated the market in 2022 and electrophysiology ablation catheters segment is expected to be fastest growing during forecast period.
• Based on indication, the market is segmented into atrial fibrillation (AF), atrial flutter, atrioventricular nodal reentry tachycardia (AVNRT), wolff-parkinson-white syndrome (WPW), and others. The atrial fibrillation (AF) segment dominated the market in 2022 and is expected to be fastest growing during forecast period.
• Based on country, the APAC electrophysiology market is segmented into China, India, Japan, Australia, South Korea, and the Rest of APAC.

Abbott; Biotronik, Inc.; Boston Scientific Corporation; CardioFocus; GE Healthcare; Johnson & Johnson Services, Inc.; Koninklijke Philips N.V.; Medtronic; MicroPort Scientific Corporation; and Siemens Healthineers AG are among the leading companies operating in the APAC electrophysiology market.